JP Morgan Chase’s Orchestra BioMed OBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding OBIO
JP Morgan Chase's OBIO Position: Q3 2026 in Review
JP Morgan Chase increased its Orchestra BioMed (OBIO) stake by 15% in Q3 2026, buying an estimated $14.8K and bringing the position to 23,965 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #5963.
JP Morgan Chase first reported a position in OBIO in Q2 2023 and has held it in 14 quarters since. The position peaked at $198K in Q4 2024. 93 funds tracked by Wall St. Rank hold OBIO as of Q3 2026.
- JP Morgan Chase held 23,965 shares of Orchestra BioMed worth $146K as of Q3 2026.
- JP Morgan Chase bought 3,085 Orchestra BioMed shares in Q3 2026, an estimated $14.8K.
- Orchestra BioMed made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5963 holding.
- JP Morgan Chase first reported a position in Orchestra BioMed in Q2 2023 and has held it in 14 quarters since.
- JP Morgan Chase's Orchestra BioMed position peaked at $198K in Q4 2024.
- 93 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.